Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia · Delayed Price · Currency is AUD 8.16
+0.03 (0.37%)
Sep 17, 2026, 4:10 PM AEST
Clinuvel Pharmaceuticals Ratios and Metrics
Market cap in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 411 | 518 | 520 | 770 | 883 | 734 | |
Market Cap Growth | -26.96% | -0.36% | -32.41% | -12.87% | 20.40% | -51.63% |
Enterprise Value | 161 | 286 | 323 | 596 | 744 | 636 |
Last Close Price | 8.16 | 10.22 | 10.27 | 15.15 | 17.58 | 14.57 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | 12.22 | 15.28 | 14.38 | 21.60 | 28.87 | 35.14 |
Forward PE | 11.69 | 13.65 | 13.16 | 21.49 | 28.34 | 26.11 |
PS Ratio | 4.38 | 5.51 | 5.48 | 8.73 | 11.28 | 11.16 |
PB Ratio | 1.51 | 1.90 | 2.16 | 3.79 | 5.37 | 5.84 |
P/TBV Ratio | 1.51 | 1.90 | 2.16 | 3.80 | 5.37 | 5.85 |
P/FCF Ratio | 11.65 | 14.68 | 12.75 | 24.46 | 24.62 | 18.61 |
P/OCF Ratio | 11.15 | 14.05 | 12.66 | 20.77 | 23.93 | 18.40 |
PEG Ratio | 1.44 | 2.90 | 1.30 | 2.39 | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 1.72 | 3.04 | 3.40 | 6.76 | 9.50 | 9.68 |
EV/EBITDA Ratio | 3.89 | 6.95 | 7.68 | 12.09 | 16.71 | 17.68 |
EV/EBIT Ratio | 3.98 | 7.05 | 7.82 | 12.28 | 16.86 | 17.89 |
EV/FCF Ratio | 4.57 | 8.09 | 7.91 | 18.95 | 20.73 | 16.13 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.05 | 0.05 | 0.01 | 0.02 | 0.02 | 0.03 |
Debt / FCF Ratio | 0.06 | 0.06 | 0.01 | 0.03 | 0.03 | 0.03 |
Net Debt / Equity Ratio | -0.92 | -0.92 | -0.93 | -0.90 | -0.95 | -0.96 |
Net Debt / EBITDA Ratio | -6.08 | -6.08 | -5.32 | -3.71 | -3.50 | -3.34 |
Net Debt / FCF Ratio | -7.08 | -7.08 | -5.48 | -5.81 | -4.34 | -3.05 |
Asset Turnover | 0.33 | 0.33 | 0.38 | 0.42 | 0.46 | 0.52 |
Inventory Turnover | 2.01 | 2.01 | 1.52 | 0.77 | 1.33 | 3.69 |
Quick Ratio | 14.34 | 14.34 | 9.24 | 8.33 | 7.02 | 10.03 |
Current Ratio | 14.81 | 14.81 | 9.66 | 8.81 | 7.44 | 10.24 |
Return on Equity (ROE) | 13.21% | 13.21% | 16.30% | 19.39% | 21.09% | 18.62% |
Return on Assets (ROA) | 8.94% | 8.94% | 10.26% | 14.29% | 16.34% | 17.60% |
Return on Invested Capital (ROIC) | 126.71% | 144.24% | 155.46% | 236.84% | 419.57% | 190.89% |
Return on Capital Employed (ROCE) | 14.70% | 14.70% | 16.90% | 23.60% | 26.20% | 27.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | 8.24% | 6.54% | 6.95% | 4.63% | 3.46% | 2.84% |
FCF Yield | 8.58% | 6.81% | 7.84% | 4.09% | 4.06% | 5.38% |
Dividend Yield | 0.61% | 0.49% | 0.49% | 0.33% | 0.28% | 0.27% |
Payout Ratio | 7.39% | 7.39% | 6.92% | 6.93% | 6.46% | 5.92% |
Buyback Yield / Dilution | -0.73% | -0.73% | 1.27% | 1.52% | -0.08% | -1.26% |
Total Shareholder Return | -0.12% | -0.24% | 1.75% | 1.85% | 0.21% | -0.99% |